537.25MMarket Cap-2335P/E (TTM)
9.430High8.960Low370.89KVolume9.080Open9.100Pre Close3.40MTurnover0.86%Turnover RatioLossP/E (Static)58.52MShares17.01952wk High-7.39P/B397.17MFloat Cap6.06552wk Low--Dividend TTM43.26MShs Float64.540Historical High--Div YieldTTM5.17%Amplitude5.840Historical Low9.176Avg Price1Lot Size
Phathom Pharmaceuticals Stock Forum
SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT
SynOx Therapeutics has closed a $75m Series B financing round led by Forbion, HealthCap, and Bioqube Ventures to fund a Phase 3 trial of emactuzumab, a potential best-in-class treatment for Tenosynovial Giant Cell Tumour (TGCT). Emactuzumab has shown promising clinical activity with a 71% objective response rate and good tolerability in earl...
Over 25% SI this week on Finviz
may retest 6.60
A bit more to make a note
The company is also finalizing its plans to initiate an additional Phase 3 study in 2024 evaluating VOQUEZNA as an investigational As Needed treatment for episodic heartburn relief in adults with Non-Erosive GERD
News
REMINDER!
No comment yet